A phase II, randomized study of aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients-Reference-Cited by-同舟云学术

A phase II, randomized study of aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients

Published:2015-12-31 Issue:3 Volume:4 Page:393-398
ISSN:2049-9450
Container-title:Molecular and Clinical Oncology
language:en
Short-container-title:

Author:

ARIDOME KUNIAKI,MORI SHIN-ICHIROU,BABA KENJI,YANAGI MASAYUKI,HAMANOUE MASAHIRO,MIYAZONO FUTOSHI,TOKUDA KOUKI,IMAMURA HIROSHI,OGURA YOSHITO,KANEKO KOUICHI,KIJIMA FUMIO,MAEMURA KOUSEI,ISHIGAMI SUMIYA,NATSUGOE SHOJI

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology;International Journal of Clinical Oncology;2024-09-11

2. Defining the Clinical Benefits of Adding a Neurokinin-1 Receptor Antagonist to Control Chemotherapy-Induced Nausea and Vomiting in Moderately Emetogenic Chemotherapy: A Systematic Review and Meta-Analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology;2024-08-19

3. One-Day Versus Three-Day Dexamethasone with NK1RA for Patients Receiving Carboplatin and Moderate Emetogenic Chemotherapy: A Network Meta-analysis;The Oncologist;2022-04-15

4. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis;Cochrane Database of Systematic Reviews;2021-11-16

5. Evaluation of Antiemetic Therapy for Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin;Therapeutics and Clinical Risk Management;2021-01